Press release

Troy Hilsenroth appointed CEO of biolog-id

23 November 2021
Left arrow
Right arrow

Paris, November 23rd, 2021 

As part of the biolog-id international deployment and in its preparation for going public, the company’s board of directors have designated Troy Hilsenroth as CEO of biolog-id worldwide. This appointment is effective since November 1st, 2021. 

Fortified by 29 years of experience, Troy Hilsenroth has in-depth healthcare expertise. Before joining biolog-id as CEO of biolog-id LLC North-America in 2019, he was previously vice president and general manager of the medication adherence division at Omnicell, where he built and grew a global division over the last 10 years. Prior to this, he led management and staff pharmacy positions at renowned healthcare organizations. 

“After 2 years as CEO for the North American region, I’m very proud and excited to take the lead of all biolog-id activities”, declare Troy Hilsenroth. “From the very beginning, I’m convinced that biolog-id has a significant potential to contribute to the digital transformation of the healthcare industry and I am very honored to take on this new position to support the company in its preparation for going public. I’m looking forward to – together with the Board and all collaborators – writing the next chapter of this success story”. 

“As founder and Chairman of the Board of the company, I’m delighted to have Troy Hilsenroth taking these new responsibilities”, announces Jean-Claude Mongrenier. “The previous years spent in the company proven that Troy has a leading vision on how to develop our business, he has successfully deployed our solutions at major US Blood Banking institutions. We all agreed that Troy Hilsenroth is a standout leader, and the Board is confident that he will create the necessary conditions for entering in the stock market”. 

Founded in 2005, biolog-id has patented technology that allows healthcare professionals to track, trace and manage sensitive healthcare products throughout their journey, from donor to patient. With more than 100 employees, the company currently operates in 14 countries throughout North America, Europe, the Middle East, India and the Asia-Pacific region. 

About biolog-id

Biolog-id develops and implements innovative solutions, that digitally transform routine processes into actionable data supporting better operational and strategic decisions for sensitive therapeutic products. 

The information generated by biolog-id solutions is available to Healthcare Professionals at any time, enhancing their processes efficiency, work conditions and ultimately the safety of the therapeutics administered to patients. 

Biolog-id’s patented platform is utilized in North America, Europe, Middle East, India, and Asia Pacific. Biolog-id is owned by its founder, managers, and Xerys Invest. Xerys Invest is a French investment company primarily positioned on trending sectors that include healthcare & Life Sciences, renewable energy/GreenTech and new digital technologies. 

Company URL: 

Contact: Astrid Billard, 

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

Choose Location

Please select your location from the liste below so we can display your market content.